The Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU) has incorporated two new biotech companies: Biogen, a US multinational founded in 1978, especially dedicated to the development of therapies for neurodegenerative disorders, autoimmune and rare diseases; and Intercept, a biopharmaceutical company founded in New York in 2002 focused on the development and commercialisation of innovative therapies for the treatment of progressive non-viral liver diseases. With these two new additions, which join Amicus Therapeutics and Kyowa Kirin Farmacéutica last March, AELMHU now has 15 members representing 40% of the pharmaceutical and biotech companies present in Spain with orphan or ultra-orphan drugs (OMPs) marketed in Spain.